Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Peidmont Healthcare, Inc, Atlanta, Georgia, United States
OSF St. Francis Medical Center, Peoria, Illinois, United States
Hannover Medical School, Hanover, Lower Saxony, Germany
Contact: Study coordinator (Anna Saborowski, PD Dr. med.) · Saborowski.Anna@mh-hannover.de · +495115329592University Medical Center of Johannes Gutenberg University Mainz, Mainz, Rhineland-Palatinate, Germany
Contact: Study coordinator (Peter R. Galle, Prof. Dr. med.) · galle@uni-mainz.de · +49 (0) 6131 17 7276Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität, Frankfurt, Germany
Polyclinic S. Orsola-Malpighi, Bologna, Italy
Asst Grande Ospedale Metropolitano Niguarda, Milan, Italy
University Hospital Miguel Servet, Zaragoza, Aragon, Spain
Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain
University Clinic of Navarra - Pamplona, Pamplona, Chartered Community of Navarra, Spain
University Hospital Ramon y Cajal, Madrid, Madrid, Spain